Amir Landi

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
Amir Landi.png

Abdolamir Landi, MD, PhD, also known as, Amir Landi, is a senior research scientist and principal investigator in the Department of Medical Microbiology and Immunology at the University of Alberta, Canada. He serves as a member of the ME/CFS committee of the Alberta Medical Association and a Research and Medical Advisor to National ME/FM Action Network, Canada. He has been working on the immunologic aspects of ME/CFS since 2010.[1]

Dr. Landi leads the biomarker team in Professor Michael Houghton's laboratory in the Department of Medical Microbiology and Immunology at the University of Alberta, Canada, working to validate a panel of cytokine biomarkers for ME/CFS.[2]

Dr. Landi is a scientific member of the executive committee and the chair of the working group Infection & Immunity of Interdisciplinary Canadian Collaborative ME (ICanCME) Research Network.

Education[edit | edit source]

  • 1995, MD - Tehran University of Medical Sciences, Iran[3]
  • 2009, PhD - Immunovirology / Vaccinology from University of Saskatchewan, Canada[3]
  • 2010, post-doctorate fellowship - Vaccine and Infectious Disease Organization, International Vaccine Centre, Saskatoon, Saskatchewan, Canada[3]
  • 2015, post-doctorate fellowship - University of Alberta, Edmonton, Alberta, Canada

Clinical care guidelines[edit | edit source]

  • 2016, Toward Optimized Practice (TOP) ME/CFS Clinical Practice Guidelines[4]

Patents[edit | edit source]

  • 2019, Methods and compositions in diagnosis of chronic fatigue syndrome/myalgic encephalomyelitis. US Patent: 10,408,844The patent is for two assay algorithms of specific cytokines and chemokines for a serologic diagnostic test for CFS/ME. Inventors: Abdolamir Landi, David Broadhurst, D. Lorne J. Tyrrell, Michael Houghton[5]

Research studies[edit | edit source]

  • 2011, No evidence for XMRV nucleic acids, infectious virus or anti-XMRV antibodies in Canadian patients with chronic fatigue syndrome[6] - (Full text)
  • 2016, Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome[7] - (Full text)

Talks and interviews[edit | edit source]

  • 27-30 May 2015, Biomedical Research into ME Colloquium (BRMEC5), London, UK - Speech title: Cytokine and Chemokine Profiles of ME/CFS Patients.
  • 3-5 May 2018, ME/CFS Canadian Collaborative Team Conference, Montreal, Canada - Speech title: Diagnosis of ME/CFS: Can Immune Modulators Play a Role?[8]
  • 14 & 15 Dec. 2018, CIHR ME/CFS Strengthening Workshop, Montreal, Canada - Speech title: Immunobiology of ME/CFS: From pathogen discovery to pathogenesis.
  • 24 October 2019, Canadian CBC Radio, Morning Episodes
  • 28 October 2019, Canadian Global NEWS Edmonton TV interview: Global News, Health Matters

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "ME/CFS Canadian Collaborative Team Conference program" (PDF). Retrieved Mar 6, 2019. 
  2. "What's the Buzz - September". Bateman Horne Center. Sep 23, 2016. Retrieved Mar 31, 2019. 
  3. 3.03.13.2 "Amir Landi". LinkedIn. Retrieved Mar 31, 2019. 
  4. "Myalgic Encephalomyelitis/Chronic Fatigue Syn - Toward Optimized Practice (TOP) - CPGs". www.topalbertadoctors.org. Retrieved Aug 27, 2019. 
  5. "Michael Houghton Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved Nov 6, 2019. 
  6. Steffen, Imke; Tyrrell, D. Lorne; Stein, Eleanor; Montalvo, Leilani; Lee, Tzong-Hae; Zhou, Yanchen; Lu, Kai; Switzer, William M.; Tang, Shaohua; Jia, Hongwei; Hockman, Darren; Santer, Deanna M.; Logan, Michael; Landi, Amir; Law, John; Houghton, Michael; Simmons, Graham (Nov 17, 2011). "No Evidence for XMRV Nucleic Acids, Infectious Virus or Anti-XMRV Antibodies in Canadian Patients with Chronic Fatigue Syndrome". PLoS ONE. 6 (11): e27870. doi:10.1371/journal.pone.0027870. ISSN 1932-6203. PMC 3219700Freely accessible. PMID 22114717. 
  7. Landi, Abdolamir; Broadhurst, David; Vernon, Suzanne D.; Tyrrell, D. Lorne J.; Houghton, Michael (Feb 2016). "Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome". Cytokine. 78: 27–36. doi:10.1016/j.cyto.2015.11.018. 
  8. "ME/CFS Canadian Collaborative Team Conference program" (PDF). Retrieved Mar 6, 2019. 

ME/CFS - An acronym that combines myalgic encephalomyelitis with chronic fatigue syndrome. Sometimes they are combined because people have trouble distinguishing one from the other. Sometimes they are combined because people see them as synonyms of each other.

Myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

Myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

Antibody - Antibodies or immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.